Skip to content

Author

T. Friede

We have 3 of 41 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

The C-MIC II Follow-Up Study: Safety and Efficacy Results 12 months After Deactivation of Cardiac Microcurrent Therapy.

BACKGROUND The C-MIC II trial demonstrated benefits of 6 months of cardiac microcurrent (C-MIC) therapy in patients with non-ischemic heart failure with reduced ejection fraction (HFrEF). The prospective C-MIC II Follow-Up Study evaluates safety and efficacy outcomes post-device deactivation. METHODS Primary safety-r...

J. Rame, D. Kosevic, T. Kovačević-Preradović et al. · 0 citations
Open access Jul 2026

Spironolactone in the Treatment of Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Design and Baseline Characteristics of the SPIRIT-HF-DZHK08 Trial.

SPIRIT-HF addresses key evidence gaps for spironolactone in high-risk HFpEF/HFmrEF, and could inform guideline recommendations on MRA use in this cohort.

D. Zurkan, B. Pieske, J. Petutschnigg et al. · 1 citation
Open access Aug 2026

Mortality reduction with implanted defibrillator for primary prevention of sudden death after Myocardial Infarction: temporal trends in the PROFID study.

In this analysis including a large cohort of post-myocardial infarction patients with reduced LVEF, the estimated mortality reduction associated with primary prevention ICD implantation progressively decreased over time.

Alireza Sepehri Shamloo, T. Chiba, J. G. Tijssen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.